Ev-mediated delivery of binding protein-small molecule conjugates

The EV according to any one of the preceding claims, wherein the at least one small molecule agent is a drug selected from the group comprising anticancer agents, cytostatic agents, DNA or RNA intercalators, nucleosides, splicing modulators, kinase inhibitors, tyrosine kinase inhibitors such as BTK inhibitors or Bcr-Abl inhibitors, statins, NSAIDs, antibiotics, antifungals, antibacterials, anti-inflammatory agents, anti-fibrotic agents, antihypertensives, vasodilators, hormones and analogues thereof, aromatase inhibitors, esterase inhibitors, anticholinergic agents, SSRIs, BKT inhibitors, PPAR agonists, dopamine agonists, HER inhibitors, AKT inhibitors, BCR-ABL inhibitors, signal transduction inhibitors, cytokine inhibitors, ILs and ILR inhibitors, TNF and TNFR inhibitors, angiogenesis inhibitors, synthase inhibitors, oligonucleotides such as siRNA, mRNA, antisense oligonucleotides, splice-switching oligonucleotides, peptides, cell-penetrating peptides, ALK inhibitors, BRAF inhibitors, MEK inhibitors, PI3K inhibitors, neprilysin inhibitors, beta2-agonists, CRTH2 antagonists, FXR agonists, BACE inhibitors, sphingosine-1-phosphate receptor modulators, MAPK inhibitors, Hedgehog signaling inhibitors, MDM2 antagonists, LSD1 inhibitors, lactamase inhibitors, IDO inhibitors, ERK inhibitors, Chk1 inhibitors, and any derivatives, subunits, domains, or combinations thereof.

The EV according to any one of the preceding claims, wherein the binding of the at least one small molecule agent optionally makes the binding protein therapeutically active.

The EV according to any one of the preceding claims, wherein the binding protein is a fusion protein comprising a binding protein portion and an EV protein.

The EV according to any one of the preceding claims, further comprising a targeting moiety.